Testing & Purity · September 3, 2026

FDA’s 2026 Draft PSGs for Peptides: Implications for Lab Testing, Impurity Characterization, and COAs

On July 28, 2026 the FDA published revised draft product‑specific guidances (PSGs) for a set of peptide drug products. These documents articulate the agency’s current thinking about comparative analytical strategies for ANDA submissions, with particular emphasis on impurity reporting, higher‑order structure (HOS) assessment, orthogonal identity/purity testing, and evaluation of innate immune response–modulating impurities (IIRMI). For laboratory researchers and buyers who manage quality control and certificates of analysis (COAs), the draft FDA guidance provides a useful framework for what to request, what to document, and how to interpret third‑party reports in a research context.

What the 2026 drafts emphasize for analytical testing

The draft PSGs and companion FDA materials stress several recurring themes relevant to peptide analytical testing: rigorous impurity characterization with clear thresholds, orthogonal identity and purity confirmation (separation + mass spectrometry + biophysical HOS methods), and fit‑for‑purpose evaluation for potential innate immune activity. Laboratories should view the guidance as regulatory science context that informs QC expectations rather than prescriptive laboratory protocols.

Impurity reporting thresholds and comparability

The drafts recommend reporting all peptide‑related impurities above approximately 0.10% and identifying impurities above roughly 0.50%. For comparative assessments (e.g., generic vs reference listed drug), impurity levels present in the proposed product should not exceed those in the RLD, or 1.0% where applicable. Total active‑ingredient related impurities should be summed and reported. Researchers should treat these thresholds as benchmarks to guide impurity profiling and documentation in COAs and procurement records.

Orthogonal identity and purity testing

FDA reiterates the value of orthogonality: combine separation methods (RP‑HPLC, ion‑exchange, SEC) with mass spectrometry (LC‑MS, HRMS) and, where appropriate, quantitative orthogonal assays (qNMR, amino‑acid analysis). For COAs and lab reports, request chromatograms and corresponding mass spectra for principal peaks, and documentation of calibration and reference materials used to assign purity.

Higher‑order structure assessment and aggregation

Higher‑order structure assessment is an explicit element of the draft PSGs where it is applicable to the peptide. The agency recommends orthogonal biophysical methods on the finished drug product to evaluate secondary/tertiary structure and aggregation state. Common techniques cited in the literature include circular dichroism (CD), differential scanning calorimetry (DSC), NMR, FTIR, dynamic light scattering (DLS), and SEC‑MALS for sizing/oligomer assessment.

What to expect on COAs and lab reports

COAs may not include full HOS panels, but for critical comparisons you should expect at minimum:

  • Statement of which HOS assays were performed and brief method notes.
  • Comparative results or summary metrics (e.g., secondary structure signatures by CD, presence/absence of aggregates by SEC/DLS).
  • Stress or forced‑degradation summaries when provided.

Innate immune response–modulating impurities (IIRMI) testing

The drafts link aggregate and process‑related impurities to potential innate immune activity and recommend a risk‑based approach. Traditional compendial tests (endotoxin/LAL, residual host DNA, host‑cell protein assays) remain relevant, but cell‑based functional assays are needed when non‑API impurities or aggregates raise concern.

Key assay considerations for IIRMI

For laboratories considering or evaluating IIRMI data, the draft materials and the literature recommend:

  • Performing assays on formulated drug product with minimal manipulation to retain relevant matrix effects.
  • Using complementary platforms (PRR reporter lines, primary PBMCs, monocyte/macrophage assays) and multiparameter readouts (NF‑κB activation, cytokine panels, activation markers).
  • Including spike/recovery and matrix suitability controls to demonstrate assay sensitivity in the DP matrix and documenting drug tolerance and limits of detection.

Interpreting COAs and verifying lot traceability

COAs should be treated as starting points rather than the full evidentiary package. Good practice for research laboratories and buyers includes requesting the raw analytical data that support COA statements: HPLC chromatograms, LC‑MS spectra, calibration curves, and method SOP references. The literature recommends that COAs include manufacturer and lot/batch number, assigned purity, identity evidence, expiration/retest date, storage instructions, and the analytical methods used to assign purity.

Lot traceability and recordkeeping

Maintain a batch or procurement table that records vendor lot numbers, internal inventory IDs, manufacture and receipt dates, linked COAs, and any retest or bridging data. When reference materials from different lots are used, document bridging experiments and acceptance criteria. These records support reproducibility in laboratory research and retrospective investigations.

FDA peptide PSGs 2026 What to expect on COAs and lab reports research concept image
Research-focused visual context for FDA peptide PSGs 2026: What to expect on COAs and lab reports.

Documenting testing decisions for research records

Documenting why particular assays were selected or omitted is important. For each lot or study reagent, record the decision rationale (e.g., matrix interference prevented a specific HOS assay; endotoxin tested via LAL; LC‑MS used for peak identification), the SOP version, acceptance criteria, and raw data retention location. This helps maintain traceability and supports transparency in laboratory research-only contexts.

Limitations and research‑only framing

These FDA documents are draft PSGs and reflect agency thinking for regulatory submissions; they are not operational laboratory protocols. Assay selection, method development, and acceptance criteria will depend on the specific peptide, formulation, available instrumentation, and research goals. Matrix effects, assay sensitivity, and resource limitations can constrain the scope of testing. Researchers should use the draft PSGs as guidance for QC expectations and for structuring COA requests while retaining a clear research‑only context.

Practical checklist for labs and buyers

  • Request COAs with method details and raw chromatograms/spectra.
  • Verify lot traceability in procurement records (lot numbers, dates, storage).
  • Ask for orthogonal data: HPLC chromatogram + LC‑MS intact mass and HRMS peak IDs.
  • Expect HOS summaries for finished product where applicable; request sequestered raw data if critical.
  • For IIRMI concerns, ask whether cell‑based functional assays were performed and request assay qualification controls.
  • Document all testing decisions, SOP versions, and acceptance criteria in research records.

Sources and further reading

Selected sources that informed this summary are listed below and provide technical detail for laboratories interested in the regulatory background and analytical approaches.

Frequently Asked Questions

Q: Do the draft PSGs change what should appear on a COA?

A: The draft PSGs reinforce existing expectations for clear impurity reporting, identity evidence, and method disclosure. For research purposes, labs should request COAs that document methods used and ask for supporting chromatograms and spectra when available.

Q: When is higher‑order structure testing necessary?

A: The drafts recommend HOS assessment when HOS relates to product sameness or when aggregates/structural differences could affect analytical comparability. Whether to include HOS in research QC depends on the peptide, formulation, and study objectives.

Q: What should I look for in IIRMI reports?

A: Look for assay type (e.g., reporter line, PBMC), matrix controls and spike/recovery, validation/fit‑for‑purpose notes (sensitivity, drug tolerance), and multiparameter readouts. Raw data and control responses are especially informative.

Q: Are the draft PSGs final requirements?

A: No. These documents are draft guidances that reflect current FDA thinking and may change during finalization. Use them as a scientific framework while documenting any deviations or limitations in research records.

Suggested category: Quality control

Related Peptide Titans Resources

Research Sources

Primary references and source materials used for this research-focused overview:

← Back to all articles